Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
AstraZeneca's Phase III CLARITY-Gastric01 trial showed sonesitatug vedotin (Sone-Ve) cut the risk of death by 42% versus investigator's choice of chemotherapy in 2nd- and later-line CLDN18.2-positive advanced gastric/GEJ cancer, with median OS of 10.6 vs 6.4 months. In the 3rd- and later-line setting, the primary endpoint, death-risk reduction was 53%, with median OS doubled to 10.0 vs 5.0 months, and benefit was consistent across CLDN18.2 expression levels — supporting use in up to ~60% of these patients.
Key figures
- Drug Name
- Sonesitatug vedotin (Sone-Ve)
- Phase Of Trial
- Phase 3
- Trial name
- CLARITY-Gastric01
- Os hazard ratio 3 L
- 0.47 (95% CI 0.36-0.62)
- Median os 3 L months
- 10.0 vs 5.0
- Eligible patient pool
- ~60% of gastric/GEJ cancers express CLDN18.2
- Death risk reduction 3 L
- 53%
- Os hazard ratio overall
- 0.58 (95% CI 0.47-0.73)
- Median os overall months
- 10.6 vs 6.4
- Death risk reduction overall
- 42%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.